Recent events
Recent events tied to this brand in public sources.
Back to profile95 entries · Page 1 of 5
2026
Bayer raises 2026 adjusted EBITDA outlook
Bayer raised its 2026 outlook for currency-adjusted EBITDA before special items, citing stronger pharmaceutical performance in the first nine months of the year.
2026
Bayer raises outlook after pharma recovery
A WSJ headline reports that Bayer raised its outlook after a recovery in its pharma business; the supplied source does not provide further details.
2026
Monsanto secures defense verdict in Roundup trial
A Missouri jury returned a unanimous defense verdict in Monsanto's favor in a Roundup-related trial involving claims of design defect, fraud and negligence.
2026
Jury rules for Bayer in Roundup cancer trial
A St. Louis jury unanimously ruled for Bayer-owned Monsanto in a trial over claims that Roundup caused cancer. Bayer denied the claims.
2026
Jury rules for Bayer in Roundup cancer trial
A Missouri jury unanimously sided with Bayer in a trial over claims that Roundup caused cancer in three women. The women had alleged that they developed non-Hodgkin lymphoma after regularly using the weedkiller.
2026
Phylo and Bayer announce AI drug-discovery research partnership
Phylo announced a partnership with Bayer to use Phylo’s Biomni Lab AI platform in drug-discovery research, including workflows aimed at assembling scientific literature and omics evidence. The announcement was unclear about whether Bayer’s access had begun.
2026
Bayer CEO cut managers by 70%
Fortune reports that Bayer's CEO has cut the number of managers at the company by 70%, with the article indicating the company now faces the next stage of the effort.
2026
Bayer to build $2.2 billion drug manufacturing plant in New Albany
Pharmaceutical company Bayer plans to build a $2.2 billion drug manufacturing plant in New Albany, as reported by wosu.org.
2026
Bayer and Soufflé Therapeutics announce siRNA collaboration
Bayer and Soufflé Therapeutics announced a strategic collaboration and global licensing agreement to advance a heart-targeted siRNA therapy for a form of dilated cardiomyopathy.
2024
Bayer obtains exclusive rights to AlphaBio bioinsecticide
Bayer entered into an agreement with AlphaBio Control granting Bayer exclusive rights to a bioinsecticide for arable crops. The product launch is planned for 2028.
2024
Bayer introduces Iberogast in the United States
Bayer Consumer Health introduced Iberogast, a plant-based digestive relief product, to the United States. The article says it is available on Amazon and at major retailers.
2024
Bayer and Trinity Agtech announce carbon initiative collaboration
Bayer revealed a collaboration with Trinity Agtech intended to lower carbon emissions and store carbon in soil. Trinity Agtech's Sandy platform will support Bayer's Carbon Initiative by monitoring carbon levels on farms.
2024
Health Yuan and Bayer sign an exclusive license agreement for a COPD drug candidate in China
Health Yuan Pharmaceutical Group and Bayer signed an agreement granting Health Yuan an exclusive license in China to develop, commercialize, and produce a small-molecule inhibitor for COPD.
2024
Bayer and BharatCares launch Better School Program
Bayer announced a collaboration with BharatCares to launch the Better School Program at a government primary school in Himatnagar, Gujarat. The initiative is intended to benefit more than 850 students across four schools and includes STEM and computer labs, smart classrooms, and other facilities.
2024
AgPlenus and Bayer announce herbicide collaboration
AgPlenus, a subsidiary of Evogene, announced a licensing and collaboration agreement with Bayer to develop a broad-spectrum herbicide. Bayer will hold exclusive rights to develop and commercialize resulting products.
2024
Bayer advances global restructuring and job reductions
Bayer said it is adjusting its structure across its three divisions, with some positions being eliminated or redesigned and new roles created. Employees were invited to indicate whether they wished to be considered for severance benefits as the company prepared for layoffs.
2024
Bayer implements Dynamic Shared Ownership operating model
Bayer said it began using its Dynamic Shared Ownership (DSO) operating model globally, aiming to reduce management layers and bureaucracy, streamline the organization, and speed up decision-making.
2023
Bayer recalls one lot of Vitrakvi over microbial contamination
Bayer voluntarily recalled one lot of its cancer drug Vitrakvi in the United States after microbial contamination was observed during routine stability testing. Bayer identified a fungus as the source and said ingestion could pose a risk of invasive fungal infections or life-threatening pneumonia for immunocompromised patients.
2023
Bayer and Monsanto fined over Roundup advertising claims
Bayer and Monsanto were fined $6.9 million for violating an agreement with New York state to stop making misleading claims about the safety of glyphosate-based herbicides. The agreement also requires them to cease and desist from publishing or broadcasting specified safety claims in New York.
2023
FDA approves Bayer’s Ultravist for contrast-enhanced mammography
The U.S. Food and Drug Administration approved Bayer’s Ultravist-300 and Ultravist-370 for contrast-enhanced mammography, making them the only contrast agents approved for this indication, according to the report.